199 related articles for article (PubMed ID: 33120250)
1. Nullscript inhibits Cryptosporidium and Toxoplasma growth.
Murakoshi F; Bando H; Sugi T; Adeyemi OS; Nonaka M; Nakaya T; Kato K
Int J Parasitol Drugs Drug Resist; 2020 Dec; 14():159-166. PubMed ID: 33120250
[TBL] [Abstract][Full Text] [Related]
2. Activity of (1-benzyl-4-triazolyl)-indole-2-carboxamides against Toxoplasma gondii and Cryptosporidium parvum.
Khan SM; Garcia Hernandez A; Allaie IM; Grooms GM; Li K; Witola WH; Stec J
Int J Parasitol Drugs Drug Resist; 2022 Aug; 19():6-20. PubMed ID: 35462232
[TBL] [Abstract][Full Text] [Related]
3. Novel acyl carbamates and acyl / diacyl ureas show in vitro efficacy against Toxoplasma gondii and Cryptosporidium parvum.
Li K; Grooms GM; Khan SM; Hernandez AG; Witola WH; Stec J
Int J Parasitol Drugs Drug Resist; 2020 Dec; 14():80-90. PubMed ID: 33011650
[TBL] [Abstract][Full Text] [Related]
4. Boromycin Has Potent Anti-
Abenoja J; Cotto-Rosario A; O'Connor R
Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33468470
[No Abstract] [Full Text] [Related]
5. Cryptosporidium and Toxoplasma Parasites Are Inhibited by a Benzoxaborole Targeting Leucyl-tRNA Synthetase.
Palencia A; Liu RJ; Lukarska M; Gut J; Bougdour A; Touquet B; Wang ED; Li X; Alley MR; Freund YR; Rosenthal PJ; Hakimi MA; Cusack S
Antimicrob Agents Chemother; 2016 Oct; 60(10):5817-27. PubMed ID: 27431220
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of chitosan, a natural polysaccharide, against Cryptosporidium parvum in vitro and in vivo in neonatal mice.
Mammeri M; Chevillot A; Thomas M; Polack B; Julien C; Marden JP; Auclair E; Vallée I; Adjou KT
Exp Parasitol; 2018 Nov; 194():1-8. PubMed ID: 30237052
[TBL] [Abstract][Full Text] [Related]
7. Mass Spectrometry Imaging of In Vitro
Anschütz NH; Gerbig S; Ghezellou P; Silva LMR; Vélez JD; Hermosilla CR; Taubert A; Spengler B
Biomolecules; 2023 Jul; 13(8):. PubMed ID: 37627264
[No Abstract] [Full Text] [Related]
8. Immune responses to Cryptosporidium muris and Cryptosporidium parvum in adult immunocompetent or immunocompromised (nude and SCID) mice.
McDonald V; Deer R; Uni S; Iseki M; Bancroft GJ
Infect Immun; 1992 Aug; 60(8):3325-31. PubMed ID: 1639500
[TBL] [Abstract][Full Text] [Related]
9. Identification of Cryptosporidium parvum active chemical series by Repurposing the open access malaria box.
Bessoff K; Spangenberg T; Foderaro JE; Jumani RS; Ward GE; Huston CD
Antimicrob Agents Chemother; 2014 May; 58(5):2731-9. PubMed ID: 24566188
[TBL] [Abstract][Full Text] [Related]
10. Stable expression of mucin glycoproteins GP40 and GP15 of Cryptosporidium parvum in Toxoplasma gondii.
Li M; Sun X; Chen H; Li N; Feng Y; Xiao L; Guo Y
Parasit Vectors; 2024 Feb; 17(1):65. PubMed ID: 38360646
[TBL] [Abstract][Full Text] [Related]
11. Systemic efficacy on
Diawara EH; François A; Stachulski AV; Razakandrainibe R; Costa D; Favennec L; Rossignol JF; Gargala G
Parasitology; 2021 Jul; 148(8):975-984. PubMed ID: 33775260
[TBL] [Abstract][Full Text] [Related]
12. Dual Transcriptomics To Determine Gamma Interferon-Independent Host Response to Intestinal Cryptosporidium parvum Infection.
Gallego-Lopez GM; Mendoza Cavazos C; Tibabuzo Perdomo AM; Garfoot AL; O'Connor RM; Knoll LJ
Infect Immun; 2022 Feb; 90(2):e0063821. PubMed ID: 34928716
[TBL] [Abstract][Full Text] [Related]
13. Drug repurposing screen reveals FDA-approved inhibitors of human HMG-CoA reductase and isoprenoid synthesis that block Cryptosporidium parvum growth.
Bessoff K; Sateriale A; Lee KK; Huston CD
Antimicrob Agents Chemother; 2013 Apr; 57(4):1804-14. PubMed ID: 23380723
[TBL] [Abstract][Full Text] [Related]
14. RNA-Based Therapy for Cryptosporidium parvum Infection: Proof-of-Concept Studies.
Castellanos-Gonzalez A; Sadiqova A; Ortega-Mendez J; White AC
Infect Immun; 2022 Jul; 90(7):e0019622. PubMed ID: 35647663
[No Abstract] [Full Text] [Related]
15. Coccidial infection in immunosuppressed mice: prophylaxis and treatment with dehydroepiandrosterone.
Khalifa AM; Ibrahim IR; el-Kerdany ED
East Mediterr Health J; 2000; 6(5-6):908-18. PubMed ID: 12197348
[TBL] [Abstract][Full Text] [Related]
16. Apicomplexan infections in the gut.
Wilhelm CL; Yarovinsky F
Parasite Immunol; 2014 Sep; 36(9):409-20. PubMed ID: 25201405
[TBL] [Abstract][Full Text] [Related]
17. A novel CDPK1 inhibitor--a potential treatment for cryptosporidiosis in calves?
Lendner M; Böttcher D; Delling C; Ojo KK; Van Voorhis WC; Daugschies A
Parasitol Res; 2015 Jan; 114(1):335-6. PubMed ID: 25398685
[TBL] [Abstract][Full Text] [Related]
18. Bovine antibody against Cryptosporidium parvum elicits a circumsporozoite precipitate-like reaction and has immunotherapeutic effect against persistent cryptosporidiosis in SCID mice.
Riggs MW; Cama VA; Leary HL; Sterling CR
Infect Immun; 1994 May; 62(5):1927-39. PubMed ID: 8168959
[TBL] [Abstract][Full Text] [Related]
19. Fulminant cryptosporidiosis associated with digestive adenocarcinoma in SCID mice infected with Cryptosporidium parvum TUM1 strain.
Certad G; Creusy C; Guyot K; Mouray A; Chassat T; Delaire B; Pinon A; Sitja-Bobadilla A; Alvarez-Pellitero P; Praet M; Cuvelier C; Dei-Cas E
Int J Parasitol; 2010 Nov; 40(13):1469-75. PubMed ID: 20708621
[TBL] [Abstract][Full Text] [Related]
20. On-target inhibition of Cryptosporidium parvum by nitazoxanide (NTZ) and paclitaxel (PTX) validated using a novel MDR1-transgenic host cell model and algorithms to quantify the effect on the parasite target.
Yang B; Yan Y; Wang D; Zhang Y; Yin J; Zhu G
PLoS Negl Trop Dis; 2023 Mar; 17(3):e0011217. PubMed ID: 36972284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
